Over the years, scientific studies have shown that patients with wounds, grafts, ulcers or diabetic foot receiving oxygen at high concentrations within a hyperbaric chamber evolve more rapidly than those who do not complement the usual treatment with this therapy. In other words, Hyperbaric Oxygenation favors healing in wounds of any kind and greatly reduces the risks of amputation, even in advanced cases.
Healing is a complex process and different factors can slow it down. When a wound becomes chronic, the patient is more exposed to infections and has to undergo other surgical processes, which implies greater possibilities of complications together with emotional stress for the patient and high costs for the health system. Hyperbaric chamber treatment accelerates healing times by virtue of the greater diffusion of oxygen to the tissues that stimulates the formation of collagen, decreases the risk of infections, favors the angiogenesis process and has anti-inflammatory effects.
The formation of new blood vessels together with the increase in the number of fibroblasts and the deposit of collagen, lead the proliferative phase of the cicatrization, generating granulatory tissue. The increase of the phagocytic and bactericidal function improves the efficiency of the process of cleaning of cellular debris and the defense against microorganisms that could slow cicatrization. This is very important for diabetic patients, in immunosuppressive treatment or with congenital or acquired immunodeficiencies, whose immune system is usually more compromised.
In conclusion, HBOT is safe, noninvasive and adjuvant in the treatment of chronic and acute wounds. The increase in oxygen available in the blood plasma benefits the arrival of oxygen to the wounds, favors the formation of new blood vessels (angiogenesis), the proliferation of fibroblasts, the arrival of stem cells to the injury, the collagen synthesis and the local immune response.
Use of hyperbaric oxygenation for wound management. Juan Enrique Berner, Pedro Vidal, Patrick Will, Pablo Castillo.
Comments are closed.